$XBI $85.51 | -4.55%
Covid Updates
$TFFP -8.5% TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19 source
Pipeline Updates
$PRVB +14.1% Provention Bio Resubmitting Biologics License Application for Delay of Clinical Type 1 Diabetes in At-Risk Individuals Following Type B Meeting with the FDA source
$MRNA -4.1% IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology source
$TRVN -5.4% Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical source
$LPCN +1.5% Lipocine Announces Peer-Reviewed Publication of Phase 3 Study Results for TLANDO® source
$BBIO -8.1% bridgebio pharma announces dosing of first patient in phase 1/2 trial of investigational gene therapy for congenital adrenal hyperplasia (cah) source
$SLS -6.9% SELLAS Life Sciences Announces IND Acceptance for First Clinical Trial of GPS in China source
$TSHA -10.9% TAYSHA GENE THERAPIES ANNOUNCES POSITIVE INITIAL BIOMARKER DATA FOR TSHA-101, THE FIRST BICISTRONIC GENE THERAPY IN CLINICAL DEVELOPMENT, DEMONSTRATING NORMALIZATION OF Β-HEXOSAMINIDASE A ENZYME ACTIVITY IN PATIENTS WITH GM2 GANGLIOSIDOSIS source
$GLTO +1.3% Galecto Publishes Results Showing Safety and Efficacy of the GB0139 Inhaled Galectin-3 Inhibitor in Hospitalized COVID-19 Patients on Standard of Care source
$ADAG -6.9% Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116 source
$ONCY -3.3% Oncolytics Biotech® Partner Adlai Nortye Advances to the Second Dose Escalation Cohort of the Chinese Bridging Trial Evaluating Pelareorep-Paclitaxel Combination Treatment in Breast Cancer source
Business Updates
$EPZM -44.2% Epizyme Announces Pricing of Public Offering of Common Stock source
Posted by FS/JM
Comments